DE1617521C3 - Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen - Google Patents

Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen

Info

Publication number
DE1617521C3
DE1617521C3 DE1617521A DEH0062521A DE1617521C3 DE 1617521 C3 DE1617521 C3 DE 1617521C3 DE 1617521 A DE1617521 A DE 1617521A DE H0062521 A DEH0062521 A DE H0062521A DE 1617521 C3 DE1617521 C3 DE 1617521C3
Authority
DE
Germany
Prior art keywords
solutions
sulfonamide
preparation
potentiator
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1617521A
Other languages
German (de)
English (en)
Other versions
DE1617521A1 (de
DE1617521B2 (de
Inventor
Heinrich Dr. Klaeui
Walter Dr. Rehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE1617521A1 publication Critical patent/DE1617521A1/de
Publication of DE1617521B2 publication Critical patent/DE1617521B2/de
Application granted granted Critical
Publication of DE1617521C3 publication Critical patent/DE1617521C3/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Medicinal Preparation (AREA)
DE1617521A 1966-05-09 1967-04-24 Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen Expired DE1617521C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH671666 1966-05-09

Publications (3)

Publication Number Publication Date
DE1617521A1 DE1617521A1 (de) 1972-02-10
DE1617521B2 DE1617521B2 (de) 1979-01-04
DE1617521C3 true DE1617521C3 (de) 1979-09-06

Family

ID=74187416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1617521A Expired DE1617521C3 (de) 1966-05-09 1967-04-24 Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen

Country Status (16)

Country Link
US (1) US3551564A (enExample)
JP (1) JPS5017524B1 (enExample)
BE (1) BE698102A (enExample)
CH (1) CH544053A (enExample)
DE (1) DE1617521C3 (enExample)
DK (1) DK117520B (enExample)
ES (1) ES340262A1 (enExample)
FI (1) FI48975C (enExample)
FR (1) FR1523606A (enExample)
GB (1) GB1176395A (enExample)
GR (1) GR35814B (enExample)
IL (1) IL27876A (enExample)
IT (1) IT1143624B (enExample)
NL (1) NL140736B (enExample)
NO (1) NO127486B (enExample)
SE (1) SE348112B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZM3271A1 (en) * 1970-03-13 1972-10-23 Wellcome Found Improvements in or relating to injectable therapeutic compositions
US3728452A (en) * 1971-01-20 1973-04-17 Abic Ltd Water-soluble composition comprising sulfadimidine and pyrimethamine
IT1044231B (it) * 1972-03-16 1980-03-20 Hoffmann La Roche Combinazione di sostanze attive utile per combattere infezioni da batteri gram positivi e gran negativi
DE2342213C3 (de) * 1972-10-12 1979-10-18 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Verwendung von potenzierten SuIf onamiden bei der Behandlung oder Verhinderung von Fischinfektionen
US3985876A (en) * 1973-01-05 1976-10-12 Burroughs Wellcome Co. Chemotherapeutic solutions containing a sulphur and a salt of a 2,4-diamino-5-benzylpyrimidine
GB1485382A (en) * 1973-09-24 1977-09-08 Wellcome Found Injectable therapeutic compositions
GB1485383A (en) * 1973-09-24 1977-09-08 Wellcome Found Injectable non-aqueous therapeutic compositions
US4039543A (en) * 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
DK136934B (da) * 1976-02-06 1977-12-19 Rosco As Fremgangsmåde til fremstilling af en klar, stabil, injicerbar opløsning indeholdende et sulfonamid og en potentiator.
DE2631780C3 (de) * 1976-07-15 1981-11-19 Basf Ag, 6700 Ludwigshafen Sulfonamid-Trimethoprim-Lösungen
DE2731013C2 (de) * 1977-07-08 1982-07-15 Lentia Gmbh Verfahren zur Herstellung einer wäßrigen Infusionslösung
EP0006987A1 (en) * 1978-05-24 1980-01-23 The Wellcome Foundation Limited 2,4-Diamino-5-benzylpyrimidines, especially for the treatment of microbial infections, pharmaceutical compositions containing these compounds and processes for preparing these compounds
DE2963408D1 (en) 1978-08-01 1982-09-16 Ciba Geigy Ag Stable medicinal solution on the basis of 2,6-diamino-5-(3',4',5'-trimethoxybenzyl)-pyrimidine(trimethoprim) and a sulphonamide, process for preparing and using it
US4303643A (en) * 1979-07-05 1981-12-01 Pfizer Inc. Sulfonamide compositions
HU180740B (en) * 1979-11-27 1983-04-29 Egyt Gyogyszervegyeszeti Gyar Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity
AR220263A1 (es) * 1980-02-19 1980-10-15 Bago Lab Sa Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad
CH647412A5 (de) * 1980-03-25 1985-01-31 Hoffmann La Roche Pharmazeutische praeparate.
US4374826A (en) * 1980-07-21 1983-02-22 Pfizer Inc. Sulfonamide compositions
EP4417701A4 (en) * 2021-10-12 2025-03-05 Daan Gene Co., Ltd. IN VITRO PRESERVATIVES FOR DIAGNOSTIC REAGENTS AND USE THEREOF

Also Published As

Publication number Publication date
CH544053A (de) 1973-11-15
DE1617521A1 (de) 1972-02-10
GR35814B (el) 1968-11-04
IT1143624B (it) 1986-10-22
US3551564A (en) 1970-12-29
GB1176395A (en) 1970-01-01
FR1523606A (fr) 1968-05-03
FI48975C (fi) 1975-03-10
NL140736B (nl) 1974-01-15
DK117520B (da) 1970-05-04
JPS5017524B1 (enExample) 1975-06-21
NL6706474A (enExample) 1967-11-10
SE348112B (enExample) 1972-08-28
IL27876A (en) 1971-10-20
BE698102A (enExample) 1967-11-08
FI48975B (enExample) 1974-12-02
ES340262A1 (es) 1968-06-01
NO127486B (enExample) 1973-07-02
DE1617521B2 (de) 1979-01-04

Similar Documents

Publication Publication Date Title
DE1617521C3 (de) Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen
DE69104724T2 (de) Florfenicol enthaltendes arzneimittel.
EP0177870B1 (de) Stabilisierte Injektionslösungen von Piroxicam
EP0136470A2 (de) Injizierbare Lösung zur Behandlung von Entzündungen
DE4139017C2 (de) Wäßrige Piroxicam-Lösungen und Verfahren zu ihrer Herstellung
DE3623620C2 (enExample)
EP0187315A2 (de) Basische Zubereitungen von Chinoloncarbonsäuren
DE602005002495T2 (de) Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat
DE3416609A1 (de) 2-amino-3-ethoxycarbonylamino-6-(p-fluor-benzylamino)- pyridin-gluconat und pharmazeutische zubereitungen, die diese substanz enthalten
EP0007591B1 (de) Stabile flüssige Arzneimittelformulierung auf Basis von 2,6-Diamino-5-(3',4',5'-trimethoxybenzyl)-pyrimidin(Trimethoprim) und einem Sulfonamid, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2400218A1 (de) Pharmazeutische formulierungen
DE2627706C2 (de) Verfahren zur Herstellung von neutralen beständigen, mit Wasser zu klaren Lösungen verdünnbaren Sulfonamid-Potentiatorlösungen
DE2731013C2 (de) Verfahren zur Herstellung einer wäßrigen Infusionslösung
DE68903937T2 (de) Waessrige elcatonin-loesung enthaltende arzneizubereitung.
DD253569A5 (de) Verfahren zur herstellung von basischen zubereitungen von chinoloncarbonsaeuren
EP0653210B1 (de) Intravenös verabreichbare wässrige Lösung von Sulfametrol und Trimethoprim
DE2461570C3 (de) Arzneimittel für die Behandlung bakterieller Infektionen der Augen und/oder der Ohren und Verfahren zu ihrer Herstellung
DE1792448C3 (de) Verfahren zur Herstellung von zur parenteralen Verabreichung geeigneten stabilen Lösungen von therapeutisch anwendbaren Benzodiazepinderivaten
DE3237284C2 (enExample)
AT399817B (de) Intravenös verabreichbare wässrige sulfametrollösung und verfahren zu ihrer herstellung
DE2538678A1 (de) Injizierbare loesungen
DE2445401C3 (de) Injizierbare, einphasige Zubereitung und Verfahren zu ihrer Herstellung
DE3530821C2 (de) Luprostiolhaltige Lösung
DE1692515A1 (de) Sulfachinoxalin enthaltende Zubereitungen und Verfahren zu deren Herstellung
DE1417343C (de) Flüssige stabile Arzneimittel auf der Basis von Magnesiumkomplexsalzen des Oxytetracycline. Arun: Chas. Pfizer & Co Inc., Brooklyn, N.Y. (V.St.A.); Ttr: Beil, Dr. W.; Hoeppener, A.; Rechtsanwälte, 6230 Frankfurt-Höchst

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)